New painkiller aims to replace opioids after skin cancer surgery

NCT ID NCT07575230

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new non-opioid drug, suzetrigine, to the standard opioid painkiller hydrocodone/acetaminophen for pain after Mohs skin cancer surgery. Researchers want to see if suzetrigine can control pain just as well while reducing the need for opioids. The trial involves 75 adults aged 18-89 who are having Mohs surgery for skin tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Suzetrigine

What this could lead to

If successful, suzetrigine could offer a non-opioid option for managing pain after skin cancer surgery, reducing reliance on opioids.

What could go wrong

This is a small, early-phase trial with only 75 participants. The drug may not control pain as well as standard care, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MOHS MICROGRAPHIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baylor University Medical Center

    Dallas, Texas, 75246, United States